Clinical Characteristics and Long Term Impact on Pediatric COVID-19 in Taiwan

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeUp to 18
SponsorNational Taiwan University Hospital

About this trial

This project will study severe COVID-19 related factors, host genes, biomarkers, and prognosis of severe encephalitis in children, and conduct:

1. Retrospective clinical analysis of children with COVID-19, to analyze the clinical manifestations of children with new crown infection, and to find the relevant factors of severe disease. 2. Prospective acceptance in the acute phase: mainly to understand the correlation between the interaction of host factors, viruses and microorganisms and the severity. 3. Children's long COVID-19 Tracking Team An integrated outpatient clinic for "Long COVID-19 Syndrome in Children" will be established to conduct systematic tracking of body, lung function, nerves and psychology. Children with neurological complications or other confirmed diagnoses will undergo physical, neurological, pulmonary function and brain MRI and neurophysiological examinations, sleep examinations, and conduct psychiatric clinical diagnostic interviews to establish a psychiatric diagnosis. Status and family social function, the intelligence development status was examined by intelligence test, and cognitive function was measured by neuropsychological test. Understand the microbial phase, immune function and incidence of allergic diseases after long-term new coronavirus infection. 4. Seroepidemiological Study Group Exploring the seroepidemiology of different groups of health care workers and non-health care workers will allow us to better understand the magnitude of natural infection among children and age groups in the community and the infection profile of health care workers during this period.

This trial includes multiple groups of prospective cases to explore the impact of the new coronavirus on children and the mechanism of severe illness, and integrates various specialties and branches of the Children's Hospital to conduct a summary trial, which is expected to understand children's new crown and community epidemiology, children infected with new crown Clinical manifestations of the virus, risk factors and effects on various systems, combined with host microbiome, immune function analysis and whole-exome sequencing, to improve the detection of new coronavirus (including long-term new coronary syndrome and pediatric multisystem inflammatory syndrome). Mechanisms of host factors and interactions with microbes to improve outcomes and severe incidence in children.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

COVID-19 positive cases

Disqualifiers

You have metal substances that cannot be removed or implanted, such as: braces, metal nails, artificial electronic ears, heartbeat pacemakers, etc. Because of the inability to perform brain MRI, it is not suitable to participate in this trial.

Have major physical diseases.

Sensory impairment, such as deafness.

Movement disorders, such as cerebral palsy.

Trial population

COVID-19 positive cases younger than 18 years old

Trial design

Design model

Case-control

Time perspective

Prospective

Treatments tested in this trial

  • sequelae tracking

    Other intervention

    An integrated outpatient clinic for "Long COVID-19 Syndrome in Children" will be established to conduct systematic tracking of body, lung function, nerves and psychology. Children with neurological complications or other confirmed diagnoses will undergo physical, neurological, pulmonary function and brain MRI and neurophysiological examinations, sleep examinations, and conduct psychiatric clinical diagnostic interviews to establish a psychiatric diagnosis. Status and family social function, the intelligence development status was examined by intelligence test, and cognitive function was measured by neuropsychological test. Understand the microbial flora, immune function and incidence of allergic diseases after long-term COVID-19 infection

Treatment groups

3,000 Participants
are divided into 5 treatment groups
Group A: Clinical Characteristics of pediatric COVID-19 by the retrospective research group1 intervention
Group B: acute case receiving group (including children with multisystem inflammatory syndrome)1 intervention
Group C: children's long COVID-19 tracking group1 intervention
Group D: seroepidemiological research group1 intervention
Group E: healthy control group1 intervention

Trial outcomes

Primary outcomes

1

risk factor and complication

Clinical symptoms, for example: cough, Headache, rash......etc.

Time frame
over 3 months
2

Multidimensional Fatigue Inventory, MFI)-20

for long COVID-19 children and family

Time frame
one month
3

seropositive rate of COVID-19

Anti-SARS-CoV-2 ELISA assay

Time frame
one day

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.